MYOV Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (9 Mar 2023 @ 16:01):

Stats
Today's Volume	2.26M
Average Volume	1.09M
Market Cap	2.62B
EPS	$0 ( 2023-07-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-14.05
ATR14	$0.0590 (0.22%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-10	Valente Nancy	Sell	3 673	Common Shares
2023-03-10	Valente Nancy	Sell	36 892	Stock Options (Right to Buy)
2023-03-10	Potter Myrtle S	Sell	3 673	Common Shares
2023-03-10	Potter Myrtle S	Sell	45 000	Stock Options (Right to Buy)
2023-03-10	Potter Myrtle S	Sell	58 608	Stock Options (Right to Buy)

INSIDER POWER
71.95
Last 100 transactions
Buy: 52 768 183 \| Sell: 8 648 674

Volume Correlation

Long: 0.03 (neutral)

Short: -0.75 (moderate negative)

Signal:(61.005) Neutral

Myovant Sciences Ltd Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Myovant Sciences Ltd Correlation - Currency/Commodity

0.13
( neutral )

0.00
( neutral )

-0.23
( neutral )

0.74
( moderate )

-0.40
( neutral )

Myovant Sciences Ltd Financials

Annual	2022
Revenue:	$230.97M
Gross Profit:	$179.42M (77.68 %)
EPS:	$-2.22

Q3	2023
Revenue:	$100.23M
Gross Profit:	$66.00M (65.85 %)
EPS:	$-0.590

Q2	2023
Revenue:	$104.82M
Gross Profit:	$77.46M (73.90 %)
EPS:	$-0.470

Q1	2023
Revenue:	$116.49M
Gross Profit:	$93.56M (80.32 %)
EPS:	$-0.220

Financial Reports:

No articles found.

Myovant Sciences Ltd

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.